Day 1. Friday, 13 October 2023

1.50pm to 8pm




Moderators: Dr. Salha Bujassoum & Dr. Cicy Mary Jacob

1pm to 1.50pm



1.50pm to 2.05pm

Welcome and Opening Remarks

Dr. Mohamed Salem Jaber Al-Hassan
CEO & Medical Director, NCCCR
Chairman, Corporate Cancer Services, HMC

Dr. Mohammed Ussama Al Homsi
Deputy Medical Director for Education, Research and Quality, Senior Consultant Medical Oncologist, NCCCR

2.05pm to 2.25pm

Breast Cancer - Local Regional Adjuvant Track (Abstract 501): Efficacy and Safety Results by Age in Monarche: adjuvant abemaciclib combined with endocrine therapy (ET) in patients with HR+, HER2-, node-positive, high-risk early breast cancer (EBC)

Dr. Salha Bujassoum
Chair of Medical Oncology and Palliative Care, Senior Consultant Medical Oncologist, NCCCR

2.25pm to 2.45pm

Breast Cancer - Local Regional Adjuvant Track (Abstract LBA500): Phase III NATALEE trial of ribociclib + endocrine therapy as adjuvant treatment in patients with HR+/HER2− early breast cancer

Dr. Francois Calaud
Senior Consultant Medical Oncologist, NCCCR

2.45p to 3.05pm

Breast Cancer - Local Regional Adjuvant Track (Abstract 503): Effects of ovarian ablation or suppression on breast cancer recurrence and survival: Patient-level meta-analysis of 14,993 pre-menopausal women in 25 randomized trials

Dr. Nabeeha Karadawi
Consultant Medical Oncologist, NCCCR

3.05pm to 3.20pm


3.20pm to 3.40pm

Prayer & Coffee Break

Moderators: Dr. Nabeeha Karadawi & Dr. Francois Calaud

3.40pm to 4pm

Breast Cancer - Metastatic (Abstract 1003): Final overall survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC)

Dr. Ahlam Yousif
Consultant Medical Oncologist, NCCCR

4pm to 4.20pm

Breast Cancer - Metastatic (Abstract 1007): Randomized trial of fixed dose capecitabine compared to standard dose capecitabine in metastatic breast cancer: The X-7/7 trial

Dr. Cicy Mary Jacob
Consultant Medical Oncologist, NCCCR

4.20pm to 4.40pm

Breast Cancer - Metastatic (Abstract LBA1000): Primary outcome analysis of the phase 3 SONIA trial (BOOG 2017-03) on selecting the optimal position of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors for patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC)

Dr. Mohammed Gaber
Medical Oncologist, NCCCR

4.40pm to 5pm

Gynecologic (Abstract 5509): Final survival analysis of the phase III OVHIPEC-1 trial of hyperthermic intraperitoneal chemotherapy in ovarian cancer after 10-year follow-up

Dr. Hind El Malik
Senior Consultant Medical Oncologist, NCCCR

5pm to 5.20pm

Gynecologic (Abstract 5503): Dostarlimab for primary advanced or recurrent (A/R) endometrial cancer (EC): Outcomes by blinded independent central review (BICR) of the RUBY trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)

Dr. Shaza Bek
Medical Oncologist, NCCCR

5.20pm to 5.35pm


5.35pm to 5.55pm

Prayer & Coffee Break

Moderators: Dr. Hind El Malik & Dr. Asma El Hassan

5.55pm to 6.10pm

Symptom and Survivorship (Abstract 12000): A multicenter randomized controlled trial (RCT) for the effectiveness of Comprehensive Geriatric Assessment (CGA) with extensive patient coaching on quality of life (QoL) in older patients with solid tumors receiving systemic therapy: G-oncoCOACH study

Ms. Wafa AlSaadi
Clinical Nurse Specialist

6.10pm to 6.25pm

Symptom and Survivorship (Abstract 12006): Reduced symptom burden after implementation of an electronic symptom management program

Ms. Asma Younus
Clinical Nurse Specialist

6.25pm to 6.40pm

Symptom and Survivorship (Abstract 1507):

A cognitive-behavioral digital therapeutic for anxiety and depression in patients with cancer: A decentralized randomized controlled trial

Ms. Gulfama AbidullahMuhammad
Clinical Nurse Specialist

6.40pm to 7pm

Developmental Therapeutics – Immunotherapy (Abstract 2509): Clinical and immune phenotypes associated with immune checkpoint inhibitor-induced autoimmune diabetes

Dr. SaidDermime
Director for Cancer Translational Research Facility, NCCCR

7pm to 7.20pm

Sarcoma (Abstract 11503): A multicenter phase II study of cabozantinib + nivolumab for patients (pts) with advanced angiosarcoma (AS) previously treated with a taxane (Alliance A091902)

Dr. Asma El Hassan
Senior Consultant Medical Oncologist, NCCCR

7.20pm to 7.40pm

Melanoma/Skin Cancers (Abstract LBA9503): Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201/KEYNOTE-942 trial

Dr. Ashraf Awadelkarim
Associate Consultant Medical Oncologist, NCCCR

7.40pm to 8pm



Closing & Dinner